Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. 4basebio PLC
  6. Summary
    4BB   GB00BMCLYF79

4BASEBIO PLC

(4BB)
  Report
Delayed Quote. Delayed London Stock Exchange - 09/27 03:00:00 am
685 GBX   --.--%
07/234BASEBIO UK SOCIETAS : Further re Conversion to UK PLC
PR
07/214BASEBIO UK SOCIETAS : Conversion to UK PLC
PR
07/014BASEBIO UK SOCIETAS : Director/PDMR Shareholding
PR
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
09/21/2021 09/22/2021 09/23/2021 09/24/2021 09/27/2021 Date
680(c) 685(c) 685(c) 685(c) 685 Last
0 2 911 200 0 0 Volume
+4.62% +0.74% 0.00% 0.00% 0.00% Change
More quotes
Estimated financial data (e)
Sales 2021 0,20 M 0,27 M 0,27 M
Net income 2021 -3,27 M -4,48 M -4,48 M
Net cash position 2021 8,69 M 11,9 M 11,9 M
P/E ratio 2021 -25,8x
Yield 2021 -
Sales 2022 0,25 M 0,34 M 0,34 M
Net income 2022 -3,53 M -4,84 M -4,84 M
Net cash position 2022 4,76 M 6,53 M 6,53 M
P/E ratio 2022 -23,9x
Yield 2022 -
Capitalization 84,4 M 115 M 116 M
EV / Sales 2021 378x
EV / Sales 2022 318x
Nbr of Employees 21
Free-Float 37,9%
More Financials
Company
4basebio PLC is a United Kingdom-based specialist life sciences company. The Company is engaged in developing next generation gene therapy technologies and solutions. The Company is focused on supplying therapeutic deoxyribonucleic (DNA) for gene therapies and DNA vaccines and also for providing solutions for delivery of the DNA based products to patients. The Company focuses to manufacture and supply synthetic DNA... 
More about the company
Ratings of 4basebio PLC
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about 4BASEBIO PLC
07/234BASEBIO UK SOCIETAS : Further re Conversion to UK PLC
PR
07/214BASEBIO UK SOCIETAS : Conversion to UK PLC
PR
07/014BASEBIO UK SOCIETAS : Director/PDMR Shareholding
PR
06/304BASEBIO UK SOCIETAS : Result of AGM
PR
06/224BASEBIO UK SOCIETAS : Application filed for protected linearised synthetic DNA
PR
06/224basebio UK Societas Announces Application Filed for Protected Linearised Synthetic DNA
CI
06/184BASEBIO UK SOCIETAS : Annual General Meeting 2021
PR
06/044BASEBIO UK SOCIETAS : Notice of AGM and Posting of Accounts
PR
06/034BASEBIO UK SOCIETAS : Final Results
PR
06/034Basebio UK Societas Reports Consolidated Earnings Results for the Year Ended 31 Decemb..
CI
04/274BASEBIO UK SOCIETAS : Evaluation licence for muscular dystrophy vector
PR
04/274basebio UK Societas Signs Research Collaboration and Evaluation License Agreements wit..
CI
02/264BASEBIO UK SOCIETAS : Director/PDMR Shareholding
PR
02/224BAO UK : 4basebio UK Societas - Holding(s) in Company
PR
02/194BAO : 4basebio UK Societas - Holding(s) in Company
PR
More news
News in other languages on 4BASEBIO PLC
06/23PTA-NEWS : 4basebio UK Societas: Patentanmeldung - Anmeldung für geschützte linearisierte ..
More news
Chart 4BASEBIO PLC
Duration : Period :
4basebio PLC Technical Analysis Chart | 4BB | GB00BMCLYF79 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 6,85 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Timothy Paul McCarthy Independent Non-Executive Chairman
Hansj÷rg Plaggemars Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
4BASEBIO PLC0.00%115
MODERNA, INC.311.74%173 624
LONZA GROUP AG30.56%59 611
IQVIA HOLDINGS INC.46.01%50 128
CELLTRION, INC.-23.54%31 745
SEAGEN INC.-7.88%29 353